Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS: We randomly assi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:N Engl J Med
Autores principales: Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., Smylie, M., Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M.S., Bechter, O., Maio, M., Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P.A., Long, G.V., Cebon, J., Sosman, J., Postow, M.A., Callahan, M.K., Walker, D., Rollin, L., Bhore, R., Hodi, F.S., Larkin, J.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5706778/
https://ncbi.nlm.nih.gov/pubmed/28889792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1709684
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares